Research press release


Nature Medicine

Finding patients on the road to cognitive decline



Howard Federoffたちは、細胞膜の構成成分やその誘導体である10種類の代謝産物が、バイオマーカーとなるのを発見した。このバイオマーカー群には、認知症の発症よりも前に、脳内ニューロンの初期の退行性変化が現れるという。アルツハイマー病患者に対する治療は、早い段階で始めるほど効果が上がると考えられているので、今回の知見は、認知症の臨床試験の際に患者の選択に役立つ可能性がある。

A blood profile, using ten metabolites, that can determine with 90% certainty whether a cognitively healthy elderly person will develop dementia symptoms in the next two to three years, is reported in a study published this week in Nature Medicine.

The challenge Alzheimer’s disease (AD) treatment is identifying aging individuals that are currently cognitively normal-but who may be more prone to develop dementia-before dementia onset, so that preventive therapy can be administered in a timely fashion.

Howard Federoff and colleagues found a biomarker panel of ten metabolites that are components of the cell membrane or their derivatives. This panel of biomarkers could represent early degenerative changes in neurons within the brain prior to dementia onset. As treatments aimed at individuals with Alzheimer’s disease are thought to be more likely to work if given at early stages of the disease, the findings could help with patient selection for clinical trials in dementia.

doi: 10.1038/nm.3466


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。